In an attempt to validate and extend previous findings regarding effects of germline genetic variation on cancer outcome and treatment-related toxicities via their effects on drug metabolism (Coate et al., 2010), we used a candidate gene approach to investigate the associations of GSTP1, COMT, and TPMT, three genes involved in the cisplatin metabolism pathway, with treatment outcome and cisplatin-induced neurotoxicity. Here, GSTP1 is linked to cancer.